BPC-157

Typical Range

Protocols commonly discussed for subcutaneous injection run 200–500 mcg per dose, with some clinicians using up to 1,000 mcg in specific tissue-repair contexts. Oral BPC-157 capsules are typically formulated at 500 mcg or 750 mcg, and oral dosing often lands at 500 mcg once or twice daily. Note that systemic bioavailability of oral BPC-157 in humans has not been rigorously characterized, so equivalence to injected doses is not established.

Frequency

For injectable protocols targeting localized musculoskeletal injury, once-daily dosing (often morning, with injection near the affected site) is the most frequently described cadence. Some protocols split into twice-daily dosing to maintain more stable exposure. Oral dosing for gut applications is typically once or twice daily with meals. Intra-articular and topical formulations exist but are much less standardized.

Timing Considerations

Cycle Length

The most commonly described protocol length is 4 weeks on, followed by a 2–4 week break to reassess. For persistent injuries, some clinicians extend to 6–8 weeks of continuous use. There is no established maximum duration from the human literature — long-term continuous use has not been studied in humans.

Protocol Notes

Injection-site considerations: BPC-157 is water-soluble and most compounded preparations come as a lyophilized powder requiring reconstitution in bacteriostatic water. Typical reconstitution is 5 mg of peptide in 2 mL of bacteriostatic water, yielding 2,500 mcg/mL, which means 200 mcg = 0.08 mL on an insulin syringe. Subcutaneous injection into the abdominal fat pad is the most common route for systemic effects; for localized injury, injection into tissue immediately adjacent to (not into) the affected tendon, ligament, or joint is what the animal protocols typically use. Oral vs. injected route is determined by application target: oral for GI symptoms (gastric ulcer, IBD-type inflammation, leaky gut contexts) where first-pass gut exposure is the point; injected for musculoskeletal repair where systemic or localized tissue exposure matters. Protocol variations across clinicians are significant. This reflects the absence of human dose-ranging trials rather than any single 'correct' regimen. If you are working with a clinician, they will choose based on their experience; if you are researching independently, understand that the precision implied by specific numbers is not matched by the underlying clinical evidence.

Onset

Most user-reported benefits for localized musculoskeletal applications (tendon, ligament, joint) are described as emerging within 1–2 weeks of initiating a daily protocol, though subjective pain reduction is sometimes reported within days. For gut-related applications, self-reports suggest several days to a week before noticeable change in symptoms. These timelines come almost entirely from anecdotal sources; no human trials have characterized onset curves rigorously.

Peak Effect

Anecdotally, peak effect is commonly described in the 4–8 week range of continuous daily use, which is also where most published animal protocols have been run. Whether pharmacokinetic accumulation, tissue-specific remodeling, or both drive this curve is not established. Published preclinical work typically uses 14–28 day dosing windows and does not extend to long time-courses in a single model.

After Discontinuation

BPC-157's plasma half-life in rodent models is short — minutes to a few hours — but its tissue effects appear to outlast its circulating presence, consistent with a mechanism of promoting structural repair rather than sustaining a receptor-driven state. Most users who report benefit describe those benefits persisting after cessation as long as the underlying injury has healed; effects on acute inflammation or gut irritation tend to recede more quickly once dosing stops. Rebound effects have not been systematically described.

Bloodwork & Labs

• •hs-CRP — the cheapest systemic inflammation marker; useful when the injury context is inflammatory (tendinopathy, IBD, post-surgical recovery)
• •ESR — complements hs-CRP for slower-moving inflammatory processes
• •CBC — rules out occult anemia or infection that could mimic non-response
• •Comprehensive metabolic panel including ALT/AST — baseline only, to anchor any later concern about hepatic processing during multi-month use

Functional & Performance Tests

• •Standardized pain score (VAS 0–10 or NRS) on the target tissue, recorded daily
• •Goniometer-measured range of motion for the affected joint (or the clinical equivalent your physiotherapist uses)
• •Sport- or task-specific functional test (e.g. single-leg hop distance for a knee injury, pain-free grip strength for an elbow, walking distance for a lower-back issue)
• •Diagnostic ultrasound or MRI at baseline and end-of-cycle for structural injuries — not required, but the only way to objectively document tissue-level change

When to Test

Symptom and ROM tracking daily. hs-CRP and CBC at baseline and 4–6 weeks. Imaging at baseline and at the end of a 4-week cycle if you have access.

Interpretation & Notes

BPC-157's healing effect is slow and tissue-local, so the measurement job is different from a systemic-hormone drug: you're not chasing a bloodwork number, you're documenting functional recovery against a baseline that would otherwise stagnate. The most credible at-home setup is a disciplined pain-and-function log (daily VAS plus one standardized functional test) paired with an initial and end-of-cycle imaging study for anything structural. hs-CRP is the one blood marker that moves reliably in genuinely inflammatory contexts — a 30–50% drop at 4–6 weeks alongside symptom improvement is a reasonable responder signal, but CRP can be stable in patients whose injury isn't systemically inflammatory. No validated serum biomarker tracks tendon or ligament repair directly. Basic panels are available direct-to-consumer via LabCorp, Quest, Marek Health, and Ulta Lab Tests; imaging typically requires a clinician order.

United States

BPC-157 is not FDA-approved for any medical indication and has not completed Phase II or III human trials. Its US regulatory status is in active flux as of April 2026: on April 15, 2026, HHS Secretary Kennedy directed the FDA to remove BPC-157 — alongside 11 other peptides including TB-500, GHK-Cu, MOTS-c, DSIP, Dihexa, MK-677, Melanotan II, KPV, Semax, LL-37, and Epitalon — from Category 2 (bulk drug substances presenting significant safety risks), effective April 22, 2026. This removal is not authorization to compound. BPC-157 has been referred to the Pharmacy Compounding Advisory Committee (PCAC) for review at its July 23–24, 2026 meeting, and any addition to the 503A Bulks List would require further notice-and-comment rulemaking. Until that review completes, compounding pharmacies operate in an ambiguous middle ground: no longer formally categorized as a safety risk, but not yet sanctioned for compounding. Research-chemical suppliers continue to sell BPC-157 labeled 'not for human consumption,' which is not an authorized channel for human use.

International

Regulatory treatment varies. The European Medicines Agency has not authorized BPC-157 as a medicine. The UK MHRA has not licensed it. Australia's TGA classifies it as a Schedule 4 prescription-only substance and has taken enforcement action against its unapproved sale. Canadian and most EU member-state positions mirror the US in treating it as an unapproved investigational agent. Importing personal-use quantities is restricted or prohibited in several jurisdictions.

Sports & Competition

BPC-157 is explicitly prohibited under the 2026 WADA Prohibited List, which names it under both S0 (non-approved substances) and S2 (peptide hormones, growth factors, related substances and mimetics) — a change from prior years where its prohibition was implicit under S0 alone. Prohibited at all times, both in and out of competition. Multiple athletes have faced sanctions for BPC-157 use. Athletes subject to WADA code, USADA, UKAD, or equivalent bodies must avoid it.